Microbot Medical® Strengthens Its Commercial Capabilities with the Addition of David J. Wilson to the Board of Directors
Microbot Medical (Nasdaq: MBOT) has elected David J. Wilson to its Board of Directors, strengthening its commercial capabilities as it prepares for the launch of the LIBERTY® Endovascular Robotic System. Wilson brings over 30 years of healthcare executive experience, including two decades at Johnson & Johnson where he served as Worldwide President of Cordis. He is currently CEO of InnovHeart and previously led Global Plasma at Haemonetics
The appointment aligns with Microbot's transition to a commercially focused organization, with the LIBERTY® system expected to launch in Q2 2025. Wilson replaces Yossi Bornstein, who served on the board since before the company went public in 2016. Wilson holds numerous medical device patents and has extensive experience in business strategy, R&D, and commercial product launches in the endovascular devices market.
Microbot Medical (Nasdaq: MBOT) ha eletto David J. Wilson nel suo Consiglio di Amministrazione, rafforzando le sue capacità commerciali in preparazione al lancio del LIBERTY® Endovascular Robotic System. Wilson porta oltre 30 anni di esperienza come dirigente nel settore sanitario, comprese due decadi in Johnson & Johnson, dove è stato Presidente Mondiale di Cordis. Attualmente è CEO di InnovHeart e in precedenza ha guidato la divisione Global Plasma di Haemonetics.
La nomina è in linea con la transizione di Microbot verso un'organizzazione con focus commerciale, con il sistema LIBERTY® previsto per il lancio nel secondo trimestre del 2025. Wilson sostituisce Yossi Bornstein, che era nel consiglio da prima che l'azienda diventasse pubblica nel 2016. Wilson detiene numerosi brevetti per dispositivi medici e ha una vasta esperienza in strategia aziendale, ricerca e sviluppo e lanci di prodotti commerciali nel mercato dei dispositivi endovascolari.
Microbot Medical (Nasdaq: MBOT) ha elegido a David J. Wilson para su Junta Directiva, fortaleciendo sus capacidades comerciales a medida que se prepara para el lanzamiento del LIBERTY® Endovascular Robotic System. Wilson aporta más de 30 años de experiencia ejecutiva en el sector de la salud, incluyendo dos décadas en Johnson & Johnson donde se desempeñó como Presidente Mundial de Cordis. Actualmente es CEO de InnovHeart y previamente lideró Plasma Global en Haemonetics.
El nombramiento se alinea con la transición de Microbot hacia una organización enfocada comercialmente, con el sistema LIBERTY® programado para lanzarse en el segundo trimestre de 2025. Wilson reemplaza a Yossi Bornstein, quien sirvió en la junta desde antes de que la empresa se hiciera pública en 2016. Wilson posee numerosos patentes de dispositivos médicos y cuenta con una amplia experiencia en estrategia de negocios, I+D y lanzamientos de productos comerciales en el mercado de dispositivos endovasculares.
마이크로봇 메디컬 (Nasdaq: MBOT)는 데이비드 J. 윌슨을 이사회에 선임하여 LIBERTY® 혈관 로봇 시스템 출시를 준비하는 상업적 역량을 강화했습니다. 윌슨은 존슨앤드존슨에서 전 세계 코르디스 사장으로 20년 이상 활동하며 30년 이상의 의료 경영 경험을 갖추었습니다. 현재 그는 이노바하트의 CEO이며, 이전에는 하에모네틱스에서 글로벌 플라스마를 이끌었습니다.
이번 임명은 마이크로봇이 상업적으로 초점을 맞춘 조직으로 전환하는 것과 일치하며, LIBERTY® 시스템은 2025년 2분기에 출시될 예정입니다. 윌슨은 2016년 회사가 상장되기 전부터 이사회에서 활동했던 요시 본스타인을 대신합니다. 윌슨은 수많은 의료 기기 특허를 보유하고 있으며, 의료 기기 시장에서 비즈니스 전략, 연구개발 및 상업적 제품 출시 분야에서 광범위한 경험을 쌓았습니다.
Microbot Medical (Nasdaq: MBOT) a élu David J. Wilson à son Conseil d'Administration, renforçant ainsi ses capacités commerciales alors qu'elle se prépare au lancement du LIBERTY® Endovascular Robotic System. Wilson apporte plus de 30 ans d'expérience exécutive dans le secteur de la santé, dont deux décennies chez Johnson & Johnson en tant que Président Mondial de Cordis. Il est actuellement CEO d'InnovHeart et a précédemment dirigé la division Plasma Globale chez Haemonetics.
Cette nomination s'inscrit dans la transition de Microbot vers une organisation axée sur le commerce, le système LIBERTY® devant être lancé au deuxième trimestre de 2025. Wilson remplace Yossi Bornstein, qui faisait partie du conseil depuis avant que l'entreprise ne devienne publique en 2016. Wilson détient de nombreux brevets de dispositifs médicaux et possède une vaste expérience en stratégie commerciale, recherche et développement, et lancements de produits commerciaux sur le marché des dispositifs endovasculaires.
Microbot Medical (Nasdaq: MBOT) hat David J. Wilson in seinen Vorstand gewählt und stärkt damit seine kommerziellen Fähigkeiten, während das Unternehmen sich auf den Launch des LIBERTY® Endovascular Robotic System vorbereitet. Wilson bringt über 30 Jahre Erfahrung in leitenden Positionen im Gesundheitswesen mit, darunter zwei Jahrzehnte bei Johnson & Johnson, wo er als Präsident für Cordis weltweit tätig war. Aktuell ist er CEO von InnovHeart und leitete zuvor die globale Plasma-Division bei Haemonetics.
Die Ernennung steht im Einklang mit Mikrobot's Übergang zu einer kommerziell fokussierten Organisation, wobei mit dem LIBERTY®-System im zweiten Quartal 2025 gerechnet wird. Wilson ersetzt Yossi Bornstein, der seit vor dem Börsengang des Unternehmens im Jahr 2016 im Vorstand tätig war. Wilson hält zahlreiche Patente für medizinische Geräte und verfügt über umfassende Erfahrung in Geschäftsstrategien, F&E sowie Markteinführungen im Bereich von endovaskulären Geräten.
- Appointment of experienced healthcare executive with specific endovascular market expertise
- Commercial launch of LIBERTY® system scheduled for Q2 2025
- Strategic alignment with transition to commercial focus
- None.
Mr. Wilson has a Track Record of Leading Product Launches and Achieving Revenue Growth in the Endovascular Devices Market
BRAINTREE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, is continuing its transition into a commercially focused company with the election of David J. Wilson to the Board of Directors. Mr. Wilson is a seasoned healthcare executive with a background of commercial success and revenue growth in the endovascular devices market.
Mr. Wilson’s career spans over 30 years and includes broad, global leadership expertise in business strategy and operations, R&D, commercial readiness and product launches. He dedicated two decades in roles of increasing responsibility with various Johnson and Johnson (J&J) companies, including as the Worldwide President of Cordis. David held other leadership roles at J&J companies, namely Worldwide President of Mentor, Worldwide Vice President of Ethicon R&D and Vice President of Ethicon Biosurgery. Prior to his current role, David was the President of Global Plasma at Haemonetics Corporation where he led the global commercialization of a next generation plasma collection system. David is currently the CEO of InnovHeart, an Italian-based company focused on transcatheter mitral valve replacement. He is the holder of numerous medical device patents and has served as a Board member of several educational and healthcare institutions in the US. His education includes a Bachelor of Mechanical Engineering from Auburn University, a Master of Science in Biomedical Engineering from the University of Alabama at Birmingham and a Master of Business Administration from Columbia University.
“As we transition to a commercially focused organization, it’s important that we continue to strengthen our leadership team by adding leaders with extensive commercial experience, specifically in the endovascular space. David’s guidance will be invaluable as we prepare for the commercial launch of LIBERTY® which we expect to take place during the second quarter of 2025,” commented Harel Gadot, Chairman, CEO and President.
Mr. Wilson replaced Mr. Yossi Bornstein, a Board member since before the Company became public in 2016, whose last term as a director ended in December 2024. “We want to thank Yossi for his invaluable contributions to Microbot Medical® and wish him well in his future endeavors.”
About Microbot Medical®
Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to improve the quality of care for millions of patients and providers globally. The Company has developed the world’s first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems.
Further information about Microbot Medical® is available at http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company’s need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY® Endovascular Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will grant 510(k) clearance to commercially market the LIBERTY® Endovascular Robotic System in the United States, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Investor Contact: IR@microbotmedical.com
FAQ
When is Microbot Medical (MBOT) planning to launch the LIBERTY® Endovascular Robotic System?
Who is the new Board member appointed by Microbot Medical (MBOT)?
What is David Wilson's experience in the medical device industry?
Why did Microbot Medical (MBOT) appoint David Wilson to its Board?
Who did David Wilson replace on Microbot Medical's Board?
